Pancreatic Cancer Trials

To go back to the main page, click here

S.No. Drug Name Biological Name Developer Current Development Phase Additional Information Start Date Completion Date Source
11 Detox-B adjuvant, ras peptide cancer vaccine - National Cancer Institute (NCI) I Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer. 1995 Ongoing Source
12 Detox-B adjuvant, ras peptide cancer vaccine - National Cancer Institute (NCI) I Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer. 1995 Ongoing Source
13 Detox-B adjuvant, ras peptide cancer vaccine - National Cancer Institute (NCI) I Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer. 1995 Ongoing Source
14 Detox-B adjuvant, ras peptide cancer vaccine - National Cancer Institute (NCI) I Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer. 1995 Ongoing Source
15 Detox-B adjuvant, ras peptide cancer vaccine - National Cancer Institute (NCI) I Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer. 1995 Ongoing Source
16 Detox-B adjuvant, ras peptide cancer vaccine - National Cancer Institute (NCI) I Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer. 1995 Ongoing Source
17 HyperAcute Pancreas - NewLink Genetics II The purpose of this study is to assess overall survival after treatment with a regimen of adjuvant therapy (Gemcitabine alone or with 5-FU chemoradiation) with or without HyperAcuteŽ-Pancreas (algenpantucel-L) immunotherapy in subjects who have undergone surgical resection. 2010 2014 Source
18 - HyperAcute(R)-Pancreatic Cancer Vaccine NewLink Genetics II To assess the response for subjects with pancreatic cancer that have undergone surgical resection and treatment with a vaccine given with chemotherapy and chemoradiation. 2007 2011 Source
19 cyclophosphamide GVAX pancreatic cancer vaccine Sidney Kimmel Comprehensive Cancer Center, National Cancer Institute (NCI) - This randomized clinical trial is studying the side effects of vaccine therapy and to see how well it works when given with or without cyclophosphamide in treating patients undergoing chemotherapy and radiation therapy for stage I or stage II pancreatic cancer that can be removed by surgery. 2008 2012 Source
20 Ipilimumab PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine Sidney Kimmel Comprehensive Cancer Center, National Cancer Institute (NCI) I To determine the safety profile of ipilimumab alone or in combination with a pancreatic cancer vaccine in subjects with locally advanced, unresectable or metastatic pancreatic adenocarcinoma. 2009 2011 Source
21 - GI-4000 Vaccine + Activated T Cells, Surgical Evaluation after Vaccine 4 University of Pennsylvania I The purpose of this study is to determine if it is safe to add multiple immunotherapies to standard chemotherapy and radiation for treating pancreatic cancer tumors that cannot be completely removed by surgery 2008 2009 Source



To go back to the main page, click here